NEWARK, Del.--(BUSINESS WIRE)--Terence E. Ryan, PhD, senior vice president of iBio, Inc. (OTCBB: IBPM), yesterday described the importance of improved manufacturing technologies for biosimilars to achieve the objectives of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), at the two-day open hearing “Approval Pathway for Biosimilar and Interchangeable Biological Products” held on the U.S. Food and Drug Administration’s White Oak Campus in Silver Spring, Maryland.
